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Objectives. A role for vitamin D in the pathogenesis of autoimmune and inflammatory diseases is emerging. We undertook an audit of
25-hydroxyvitamin D (25OHD) investigation and treatment in rheumatology outpatients.
Methods. Serum 25OHD requests were matched to electronic medical records from rheumatology and metabolic bone clinics (April 2006–
March 2007). Data were analysed separately for two groups, ‘Documented osteoporosis/osteopaenia’ (Group 1) and ‘General rheumatology
outpatients’ (Group 2, sub-divided by diagnosis). Hypovitaminosis D was defined by 25OHD levels <50nmol/l. Values were compared with
healthy adults to calculate geometric z-scores.
Results. A total of 263 patients were included (Group 1, n¼122; Group 2, n¼141) with an overall median 25OHD of 44nmol/l.The 25OHD
level among general rheumatology patients (median 39 nmol/l, mean z score  1.2, was statistically significantly lower than among
osteoporotic/osteopaenic patients (median 49 nmol/l, mean z score of  0.9, p<0.05 for the difference). 25OHD was lower in inflammatory
arthritis and chronic pain/fibromyalgia than in other groups. Prescribing was recorded in 100 in Group 1 (of whom 95% were prescribed
calcium/800IU cholecalciferol) and 83 in Group 2 (91% calcium/800IU). Only 31% of the patients with 25OHD <50 nmol/l would have been
identified using general guidelines for screening patients at ‘high risk’ of hypovitaminosis D.
Conclusions. Improved guidelines for managing hypovitaminosis D in rheumatology patients are needed. We found a high prevalence of
hypovitaminosis D among secondary care patients in rheumatology and widespread supplementation with 800IU cholecalciferol.
Substantially reduced levels of serum 25OHD were identified among patients with inflammatory arthritis and chronic pain.
KEY WORDS: Vitamin D deficiency, Vitamin D, Osteoporosis, Immunopathology, Autoimmune disease, Biochemical analysis, Inflammatory arthritis,
Fibromyalgia.
Introduction
Inadequate levels of serum 25-hydroxyvitamin D (25OHD) are
not only detrimental to musculoskeletal health [1] and calcium
homeostasis but may also have a role in immunopathology.
Understanding of the role of the active vitamin D hormone
(1,25-hydroxyvitamin D) in immunodysregulation via down-
regulation of Th1 immunity is increasing [2]. Indeed, it is even
hypothesized that the latitude-related prevalence of autoimmune
diseases is at least in part due to regional differences in the
prevalence of hypovitaminosis D [2]. Recently, 25OHD levels were
found to inversely correlate with disease activity scores in RA [3],
inflammatory arthritis [4] and SLE [2] but little has been published
regarding the assessment and management of 25OHD (the stored
and readily assayed metabolite) in routine clinical practice. Just as
understanding of cardiovascular risk and its profiling in rheuma-
tological practice has increased, so rheumatologists are ideally
placed to assess and manage hypovitaminosis D in the outpatient
clinic setting. We wished to audit patterns of investigation and
treatment of hypovitaminosis D (by serum 25OHD assay) in
general rheumatology patients and osteoporotic patients among
local physicians.
For rheumatology patients, there is a dearth of formal guidance
on investigation for hypovitaminosis D levels in high-risk
individuals (with no specific recommendations to guide routine
rheumatological practice). However, from a general medical
perspective, a recent consensus position statement (CSP; from
Australia) identified high-risk groups in whom a serum 25OHD
assay should be performed [5]. Here we assess whether these
guidelines would adequately identify hypovitaminosis D in
rheumatology patients.
For patients with low bone mass, we audited our vitamin D
treatment against existing UK clinical guidelines [6]. However, it is
increasingly clear that there is no ‘One size fits all’ approach to
supplementing or treating osteoporotic patients [7], and we sought
to investigate whether new guidelines are needed.
Methods
We undertook a retrospective audit of the practice of local
rheumatologists and metabolic bone physicians (n¼9) from April
2006 to March 2007; their requests for serum 25OHD analysis
(by disease category) and their prescribing of vitamin D analogues
(including preparation type; ergocalciferol, cholecalciferol, IM
or oral, physiological or pharmacological dose) in order to
identify opportunities for improvement. By matching consultant
codes to the local biochemistry database we identified 25OHD
requests in 279 patients (7.3% of all trust requests) and identified
diagnoses and prescribing from electronic medical records.
Records were anonymized and requesting and prescribing were
audited as part of standard rheumatological practice. Sixteen
patients with a documented diagnosis of hyperparathyroidism
were excluded leaving 263. Data were first separated into two
groups, ‘Documented osteoporosis/osteopaenia’ (Group 1) and
‘General rheumatology outpatients without documented osteo-
porosis/osteopaenia’ (Group 2). We audited two main aspects of
vitamin D management in secondary care; investigation and
treatment.
Standard 1—investigation
For osteoporosis (Group 1), existing UK clinical guidelines [6]
do not specify vitamin D investigation in individual patients.
Neither do standards nor recommendations exist for the
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In the absence of satisfactory national audit standards, we used
an alternative approach. Here we audited how many clinician’s
requests (during the year) for serum 25OHD would have satisfied
the ‘high risk’ category recommendation of a recent CPS on
vitamin D and adult bone health [5] (standard 100%). We sought
to establish how many patients outside these CPS categories had
hypovitaminosis D in routine practice in order to assess if these
standards were appropriate for investigation of rheumatology and
osteoporosis patients in the UK. ‘High risk’ patients selected for
our audit from the CPS were therefore (i) elderly people (>70yrs),
(ii) patients with skin-related conditions where avoidance of
sunlight (SLE) is required and (iii) patients with malabsorption
syndromes. Data on skin colour was not available.
Standard 2—treatment
For patients with low bone mass, we chose to audit our practice
against the Royal College of Physicians’ amended guidelines [6].
In osteopaenic patients, the recommendation is ‘adequate nutri-
tion with calcium and vitamin D’ and in osteoporotic patients
‘vitamin D and calcium treatment’ (as an adjunct to treatment
with other bone active agents). Therefore, our first audit standard
for Group 1 was documentary evidence of vitamin D supplemen-
tation or dietary modification advice in 100% of the patients. We
also examined documentary evidence of vitamin D supplementa-
tion or dietary modification advice in general rheumatology
patients (Group 2). A further audit standard was documentation
of vitamin D prescribing in clinic letters (standard 100%).
Vitamin D and PTH interpretation
Serum 25OHD was measured by RIA (IDS Ltd, Boldon, UK) in a
UK Clinical Pathology Accreditation (CPA) approved laboratory.
Coefficients of intra-assay (n¼10) and inter-assay (n¼25)
variation provided by the manufacturer were <10% across the
assay range (12.5–374nmol/l). RIA under-recovers the plant sterol
vitamin D metabolite 25OHD2 (an important issue if patients
have been supplemented with ergocalciferol prior to assay), such
that cross-reactivity with 25OHD2 is 75% at 50% binding of the
zero calibrator (compared with 100% for 25OHD3 and 24,25
dihydroxyvitamin D3, manufacturer’s data on file at http://
www.idsltd.com/Downloads/AA-35PL-A.pdf). 25OHD is non-
normally distributed, so geometric (transformed) z-scores of
25OHD were calculated for each patient by comparison with the
monthly mean and S.D. of 25OHD (after log-transformation to
achieve normalization) of the local adult reference interval for
healthy older adults (derived by measuring 96 healthy adults of
mean age 69 2.9 bimonthly for a year; Fig. 1) with JMP software
v5.0 (SAS Institute, Cary, USA) [8] and methods detailed
previously [9]. The reference intervals determined were validated
for the IDS assay by linear regression studies (data not shown).
The use of z-scores meant that measurements were no longer
season dependent. The mean geometric z-scores of groups could
then be compared using analysis of variance (ANOVA) and Tukey
Kramer all-pairs honest standard deviation (HSD) analysis.
Definitions of hypovitaminosis D (a level insufficient to prevent
secondary hyperparathyroidism) are controversial. In our refer-
ence interval, the local winter mean nadir in our older [median age
69, interquartile range (IQR) 67–71] healthy subjects was 50 nmol/
l (Fig. 1), which we used as a conservative cut-off for defining
hypovitaminosis D. PTH was measured using a Siemens Advia
Centaur autoanalyser (Deerfield, IL USA) using reagents and
protocols provided by the manufacturer.
Regional ethics committee (REC) approval was gained for the
healthy volunteer study. The audit was conducted in accordance
with the local code of conduct for clinical audit and data
protection rules and written confirmation was received that the
audit was outside the remit for consideration by the REC.
Results
A total of 263 patients with 25OHD requests during the audit
period were identified from the biochemistry database. One
hundred and twenty-two (46%) had documented osteoporosis/
osteopaenia (Group 1: osteoporosis 109, osteopaenia 13). The
remaining 141 (54%, mean age 54 18yrs) comprised the general
rheumatology group (Group 2: CTDs 24, chronic pain/FM 15,
degenerative and OA 25, GCA/PMR 11, inflammatory arthritis
29, soft tissue disorders 13, Others 24). Overall (general
rheumatology and osteoporosis groups combined), 25OHD was
non-normally distributed (Shapiro Wilk goodness of fit
PW<0.0001), with median 25OHD 44nmol/l (IQR 31–63). In
Group 1, median 25OHD was 49nmol/l (IQR 35–66) and in
Group 2, 39 nmol/l (IQR 27–56). Overall, the ANOVA for means
comparison of geometric transformed z-scores was statistically
significant (P¼0.0331). Hypovitaminosis D was more prevalent
in the general rheumatology patient Group 1 (Fig. 2, mean z-score
 1.2; 95% CI  1.4,  1.1) than in the osteoporosis/osteopaenia
Group 2 (mean z-score  0.9; 95% CI  1.1,  0.7; P¼0.002). The
mean z-score of 25OHD was lower in inflammatory arthritis
(mean z-score  1.6; 95% CI  2.0,  1.2; P<0.05) and chronic
pain/fibromyalgia (mean z-score  1.8; 95% CI  2.3,  1.2;
P<0.05) than other rheumatology and osteoporotic patients.
PTH levels were requested in 94/263 (36%) patients with a median
result of 42.5ng/l (IQR 29–56). Linear regression with JMP
software version 5.0 (SAS Institute) was performed, using
methods published by Bates et al. [10] (in UK participants aged
65–84yrs). Linear regression indicated an inverse linear relation-
ship between PTH and 25OHD on a loge loge scale for the whole
sample (log PTH ng/l¼5.58 50
 log Vit D nmol/l; r
2¼0.14;
P¼0.0002).
For audit Standard 1 (investigation), only 35% (92/263) of
requests would have satisfied the ‘high risk’ category recommen-
dation of a recent CPS on vitamin D and adult bone health. Of the
92 that did fulfil the audit standard, 71 were aged >70yrs. The
remaining 21 were younger than 70yrs but had either SLE or a
malabsorption syndrome. The CPS standard would have identi-
fied only 48/156 (31%) patients with vitamin D insufficiency
(<50nmol/l) of 263 patients sampled at their clinicians discretion
in secondary care. For audit Standard 2 (treatment), vitamin D
prescribing details were documented for 100/122 (82%) in Group
1 and 83/141 (59%) in Group 2, well below our audit standard of
100%. Of those with documented prescribing, 95 (95%) patients
in Group 1 were prescribed cholecalciferol 800IU/calcium
1.25–1.5g (only three had received additional pharmacolog-
ical dose ergocalciferol) during the year and four had documen-
ted intolerance. Among the 100 Group 1 patients, 51 were on
supplements at the time the serum 25OHD was checked
FIG. 1. Healthy reference interval for older East Anglian adult controls (grey filled
circles) by month [8]. General rheumatology outpatients (n¼263) are shown for
Group 1 (black filled circles) and Group 2 (open circles).
Hypovitaminosis D in rheumatology outpatients 1349(median 25OHD 61nmol, IQR 42–70) and 49 were not (median
48nmol/l, IQR 32–63, P¼0.043). Among the 83 Group 2 patients
20 were on supplements at the time the serum 25OHD was
checked (median 50nmol/l, IQR 39–68) and 63 were not (median
38nmol/l, IQR 25–57, P¼0.08). In Group 2, 91% of the patients
were prescribed treatment during the year.
Discussion
Vitamin D has pleiotropic effects beyond its calcaemic homeo-
static actions. The importance of adequate levels of vitamin D
underlies musculoskeletal health and immune function [1, 2, 11].
‘Sufficient’ stores of the pre-hormone (25OHD) are commonly
defined in studies of local populations as a level that prevents the
serum PTH from increasing, at around 50nmol/l in northern
Europe [12]. Irrespective of the time of year, patients from our
general rheumatology clinics had a lower mean vitamin D level
than healthy East Anglian adults. Out of 263 patients, 156 (59%)
in whom serum 25OHD was requested had an insufficient 25OHD
level (<50nmol/l). Increasing the threshold of serum 25OHD
requiring therapy to 75nmol/l (as many advocate for optimal
health) [13] would mean that 236/263 (90%) of rheumatology and
metabolic bone disease outpatients were vitamin D insufficient
from this sample of patients (sampled at a clinicians discretion) in
secondary care.
These findings from routine clinical practice are in agreement
with a study performed by Orbach et al. [11], where patients with
various autoimmune diseases had low levels of 25OHD. One
possible explanation for this low vitamin D level is the sun
avoidance recommended for patients with photosensitivity sec-
ondary to CTDs, and similarly the use of sun block that decreases
vitamin D production in the skin (factors not assessed in our
audit). Medications used in SLE and inflammatory arthritis have
also been found to adversely affect vitamin D metabolism (e.g.
HCQ inhibits the conversion of 25OHD to 1,25OHD2 [14]).
Patients with osteomalacia can present with diffuse pain that
may be misdiagnosed as fibromyalgia. For example, 22/26 (85%)
patients proven to have osteomalacia on bone biopsy (with only
7/26 (27%) having pseudo fractures on radionuclide bone scan)
presented with regional or widespread pain [15]. Ninety-three per-
cent of the patients presenting to a primary care facility with per-
sistent unexplained pain were found to have low vitamin D levels
(mean 30 nmol/l) [16]. Our findings confirm the association of a
low vitamin D level and unexplained pain. An unanswered ques-
tion is whether replacing this low vitamin D will alleviate the pain.
Our findings in patients with inflammatory arthritis are in
agreement with Patel et al. [4] who found associations with
25OHD insufficiency and clinically assessed disease activity in
early polyarthritis. Of particular relevance, higher stores of
25OHD appear to confer protection from (or a reduction in the
severity of) certain autoimmune diseases and OA [1, 3, 11]. The
median level among our patients with OA/degenerative disease
was 40.4 (IQR 31–55), also within the insufficient range, and
particularly interesting in light of associations between low
25OHD and incident radiographic hip OA [17].
What is apparent from our audit data is that new guidelines for
the request of serum 25OHD in high-risk patients with
osteoporosis and rheumatological diseases are needed. We used
a general audit standard over 1yr for defining a population at
high risk for hypovitaminosis D [5]. This standard would have
identified only 48/156 (31%) patients with vitamin D insufficiency
(<50nmol/l) of 263 patients sampled at their clinicians discretion
in secondary care. For newly diagnosed osteoporosis in the UK,
Ryan [7] recently made a strong case for assessing serum 25OHD
in all, with repeated measurements to ensure normalization of
serum values (because of emerging evidence that ‘standard’
preparations of calcium and vitamin D may not be universally
effective at normalizing 25OHD). In our patients with osteoporo-
sis/osteopaenia, 95% received 800IU cholecalciferol from com-
bined calcium/vitamin D tablets and those taking supplements at
the time of serum sampling for 25OHD assay had a significantly
higher level than those yet to commence on supplements. We were
unable to ascertain exactly when supplements were commenced,
but our results are generally supportive of Ryan’s study; a median
25OHD of 61 nmol (IQR 42–70) among supplemented patients
may not be in the optimal range for bone health, and more
pharmacological doses of ergocalciferol or cholecalciferol as well
as follow-up assessment of their efficacy may be required.
With regard to treatment of 25OHD insufficiency and the
prevention or alleviation of rheumatic disease, little is known in
human disease. The vitamin D receptor is highly concentrated
in the CD8-positive T cells of the thymus [18] and active vitamin
D analogues are capable of suppressing human [19] and animal
models of T-cell diseases (by suppressing the enhanced activity of
such cells) [20]. Although no randomized clinical trials of
supplementation have been conducted in arthritis, in healthy
British adults of Bangladeshi origin CRP levels were noted
to decrease by 23% in patients with hypovitaminosis D who
received an approximate daily dose of 547IU vitamin D (by
intermittent IM bolus) for 2.5yrs. This suggests a dose-dependent
anti-inflammatory effect of vitamin D [21] that warrants clinical
trial evaluation in the setting of inflammatory arthritis.
FIG. 2. Geometric z-score (upper, with mean/S.D. plot) and 25OHD (lower, with
quantile plot) by rheumatological diagnosis in all patients. ANOVA for means
comparison of z-scores was significant (P¼0.0331). Patients with inflammatory
arthritis and chronic pain/fibromyalgia had lower mean z-scores (of statistical
significance using all pairs Tukey Kramer analysis). OP&OP: osteoporosis and
osteopaenia.
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Osteoporosis is often associated with low vitamin D levels and
standard treatment in clinical practice includes oral calcium and
vitamin D supplementation or bisphosphonates. The patients in
Group 1 of our study were mostly (95%) receiving vitamin D
treatment but we were unable to ascertain exactly when the
treatment was commenced; it may have been initiated at primary
care, well before the patient was referred to our institution. This is
undoubtedly a weakness of the present study. Neither do we have
data on compliance with supplements. A further caveat to the
generalized applicability of our audit results was that although
91% of Group 2 patients were prescribed treatment, only 57% of
clinicians documented their prescribing in electronic records, a
reason for repeating the audit cycle and improving our local
practice in this regard. Around 30% (77/257) of UK laboratories
use RIA to measure vitamin D according to the last vitamin D
external quality assessment scheme (DEQAS) report of 27
October 2007 (in spite of the fact that the RIA technique for
25OHD under-recognizes D2 analogues such as ergocalciferol)
[22]. The latter is unlikely to affect overall applicability of the
results since only 3/263 patients were receiving ergocalciferol, the
remainder D3 analogues (cholecalciferol). Definitions
of hypovitaminosis D (a level insufficient to prevent secondary
hyperparathyroidism) are controversial, with some advocating a
clinical cut-off of 75nmol/l is necessary to prevent bone
pathology. Raising the threshold of vitamin D adequacy would
only strengthen the case for insufficiency among rheumatology
patients. Finally, we had insufficient numbers to investigate by
individual disease category; for instance, our inflammatory
arthritis group included AS, PsA and RA. Determining 25OHD
levels for individual conditions should now be a priority for
further work.
Conclusion
We found a high prevalence of hypovitaminosis D among
secondary care patients in rheumatology and near-universal
supplementation with 800IU daily cholecalciferol. Substantially
reduced levels of serum 25OHD were identified among patients
with inflammatory arthritis and chronic pain. 25OHD levels were
low in all rheumatology conditions when compared with a local
healthy reference interval. It is clear that clinical studies are
needed to fully assess the impact of vitamin D in patients with the
relevant rheumatological diagnoses. In light of the metabolic and
physiological effects of hypovitaminosis D in musculoskeletal and
immune health, a consensus on the requesting and treatment of
serum 25OHD levels is also needed, leading to improved
guidelines for rheumatologists.
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Rheumatology key messages
  Hypovitaminosis D is common among rheumatology patients.
  Particularly low levels are seen in inflammatory arthritis and
chronic pain/fibromyalgia.
  Vitamin D supplementation studies in specific rheumatic condi-
tions are needed.
Hypovitaminosis D in rheumatology outpatients 1351